DDInter825 DDInter1397
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Glimepiride {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Paroxetine
Glimepiride {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Glimepiride {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Paroxetine
Glimepiride {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Glimepiride {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) downregulates {v} (Gene) GRN
GRN {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Glimepiride {u} (Compound) resembles {v} (Compound) Glyburide
Glyburide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Paroxetine
Glimepiride {u} (Compound) resembles {v} (Compound) Chlorpropamide
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Erythema multiforme
Erythema multiforme {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Glimepiride {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is associated with {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Glimepiride {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} (Compound) upregulates {v} (Gene) SUV39H1
SUV39H1 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Glimepiride {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) regulates {v} (Gene) VAPB
VAPB {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Glimepiride (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Paroxetine (Compound)
Glimepiride (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Paroxetine (Compound)
Glimepiride (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Paroxetine (Compound)
Glimepiride (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Paroxetine (Compound)
Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide (Compound) downregulates GRN (Gene) and GRN (Gene) is upregulated by Paroxetine (Compound)
Glimepiride (Compound) resembles Glyburide (Compound) and Glyburide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Paroxetine (Compound)
Glimepiride (Compound) resembles Chlorpropamide (Compound) and Chlorpropamide (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Paroxetine (Compound)
Glimepiride (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is associated with HMGCR (Gene) and HMGCR (Gene) is upregulated by Paroxetine (Compound)
Glimepiride (Compound) resembles Tolbutamide (Compound) and Tolbutamide (Compound) upregulates SUV39H1 (Gene) and SUV39H1 (Gene) is downregulated by Paroxetine (Compound)
Glimepiride (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) regulates VAPB (Gene) and VAPB (Gene) is downregulated by Paroxetine (Compound)